|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
19,740,000 |
Market
Cap: |
4.17(B) |
Last
Volume: |
9,322,967 |
Avg
Vol: |
9,297,189 |
52
Week Range: |
$120.4 - $292.92 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 27 |
Insider 3/6 Months : 27.6 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
424,685 |
424,685 |
424,685 |
Total Buy Value |
$0 |
$77,751,391 |
$77,751,391 |
$77,751,391 |
Total People Bought |
0 |
1 |
1 |
1 |
Total Buy Transactions |
0 |
10 |
10 |
10 |
Total Shares Sold |
252,542 |
270,142 |
270,142 |
339,631 |
Total Sell Value |
$62,399,106 |
$66,219,580 |
$66,219,580 |
$85,688,008 |
Total People Sold |
5 |
7 |
7 |
8 |
Total Sell Transactions |
13 |
21 |
21 |
26 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Schor Chen |
President and CEO |
|
2015-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
300,000 |
|
- |
|
Kovner Bruce |
Director |
|
2015-04-06 |
4 |
B |
$1.75 |
$12,000,000 |
I/I |
6,857,143 |
15,278,610 |
2.25 |
- |
|
Gollust Keith R |
Director |
|
2015-04-06 |
4 |
B |
$1.75 |
$612,500 |
I/I |
350,000 |
3,173,383 |
2.1 |
- |
|
Wilson Robert N |
Director |
|
2015-04-06 |
4 |
B |
$1.75 |
$87,500 |
D/D |
50,000 |
754,118 |
2.39 |
- |
|
Schor Chen |
Executive VP and COO |
|
2014-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
150,000 |
|
- |
|
Schneebaum Marc R |
SVP and CFO |
|
2014-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
75,000 |
|
- |
|
Kovner Bruce |
Director |
|
2014-09-30 |
4 |
B |
$3.08 |
$923,130 |
I/I |
300,000 |
8,421,467 |
2.25 |
- |
|
Whitaker Anne Clem |
President and CEO |
|
2014-09-02 |
4 |
A |
$0.00 |
$0 |
D/D |
500,000 |
500,000 |
|
- |
|
Gollust Keith R |
Director |
|
2014-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
19,511 |
351,766 |
|
- |
|
Kovner Bruce |
Director |
|
2014-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
12,194 |
3,060,860 |
|
- |
|
Reardon William S |
Director |
|
2014-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,878 |
41,439 |
|
- |
|
Wilson Robert N |
Director |
|
2014-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,439 |
704,118 |
|
- |
|
Kovner Bruce |
Director |
|
2014-04-11 |
4 |
B |
$4.01 |
$5,012,500 |
I/I |
1,250,000 |
8,121,467 |
2.25 |
- |
|
Mcmahon Arthur |
SVP, People OperationsOfficer |
|
2014-01-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,829 |
|
- |
|
Bernitz Steven B |
SVP, Corporate Development |
|
2013-12-18 |
4 |
A |
$0.00 |
$3 |
D/D |
25,000 |
25,000 |
|
- |
|
Singh Amar |
Sr. VP, Chief Business Officer |
|
2013-12-02 |
5 |
S |
$5.00 |
$29,329 |
D/D |
(5,870) |
15,161 |
|
- |
|
Reardon William S |
Director |
|
2013-11-13 |
4 |
B |
$3.75 |
$49,999 |
D/D |
13,333 |
36,561 |
2.39 |
- |
|
Bahcall Safi R |
President and CEO |
|
2013-11-13 |
4 |
B |
$3.75 |
$75,000 |
D/D |
20,000 |
2,053,135 |
2.81 |
- |
|
Gollust Keith R |
Director |
|
2013-11-13 |
4 |
B |
$3.75 |
$562,500 |
I/I |
150,000 |
2,823,383 |
2.1 |
- |
|
Kovner Bruce |
Director |
|
2013-11-13 |
4 |
B |
$3.75 |
$18,750,000 |
I/I |
5,000,000 |
7,649,803 |
2.25 |
- |
|
Kovner Bruce |
Director |
|
2013-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
6,180,330 |
|
- |
|
Gollust Keith R |
Director |
|
2013-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
332,255 |
|
- |
|
Reardon William S |
Director |
|
2013-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
23,228 |
|
- |
|
Wilson Robert N |
Director |
|
2013-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
701,679 |
|
- |
|
Kufe Donald W |
Director |
|
2013-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
25,748 |
|
- |
|
413 Records found
|
|
Page 8 of 17 |
|
|